Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 5/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | FPR1 | P21462 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180730 | 0.81 | DGAT1 (0.52) | DGAT1MCHR1FPR2FPR1USP30 | |
| SCHEMBL180830 | 0.79 | DGAT1 (0.76) | DGAT1 | |
| SCHEMBL27758109 | 0.78 | DGAT1 (0.47) | DGAT1MCHR1FPR2FPR1USP30 | |
| SCHEMBL181069 | 0.78 | DDB1 (0.50) | DGAT1JAK2 | |
| SCHEMBL180746 | 0.77 | DGAT1 (0.56) | DGAT1MCHR1USP30 | |
| SCHEMBL180828 | 0.76 | DGAT1 (0.47) | DGAT1MCHR1FPR2FPR1EPHX2 | |
| SCHEMBL180674 | 0.74 | DGAT1 (0.41) | DGAT1FPR2FPR1EP300 | |
| SCHEMBL182490 | 0.74 | APP (0.51) | DGAT1 | |
| Hydrochloric Acid SCHEMBL181048 | 0.73 | APP (0.50) | DGAT1 | |
| SCHEMBL4323884 | 0.72 | DGAT1 (0.48) | DGAT1MCHR1FPR2FPR1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835451-B2 | Compounds | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | disclosed |
| US-20090247534-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247534-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | DGAT1 1/4885MCHR1 4196/4885FPR2 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.